Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Tacchetti

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Leukemia|April 15, 2016
Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosisM Martello, D Remondini, E Borsi, et al.
Blood Cancer Journal|January 27, 2022
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myelomaM Martello, A Poletti, E Borsi, et al.
European Journal of Haematology|March 11, 2026
Positioning of Melflufen in Heavily Pretreated RRMM Patients: Real-World Evidence in a Rapidly Evolving Therapeutic LandscapeK Mancuso, S Masci, M Talarico, et al.
Bone Marrow Transplantation|February 3, 2015
Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantationA Brioli, G Perrone, F Patriarca, et al.
Clinical and Experimental Medicine|November 25, 2025
A multicenter observational retrospective study of second-line treatment with daratumumab-bortezomib-dexamethasone (DaraVd) in multiple myeloma patients refractory to lenalidomideI Rizzello, I Sacchetti, S Barbato, et al.
Cancer Medicine|November 26, 2024
Clinical Presentation and Long-Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective StudyK Mancuso, R Mina, S Rocchi, et al.
Leukemia|October 23, 2015
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active diseaseE Zamagni, C Nanni, F Gay, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Leukemia|April 15, 2016
Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosisM Martello, D Remondini, E Borsi, et al.
Blood Cancer Journal|January 27, 2022
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myelomaM Martello, A Poletti, E Borsi, et al.
European Journal of Haematology|March 11, 2026
Positioning of Melflufen in Heavily Pretreated RRMM Patients: Real-World Evidence in a Rapidly Evolving Therapeutic LandscapeK Mancuso, S Masci, M Talarico, et al.
Bone Marrow Transplantation|February 3, 2015
Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantationA Brioli, G Perrone, F Patriarca, et al.
Clinical and Experimental Medicine|November 25, 2025
A multicenter observational retrospective study of second-line treatment with daratumumab-bortezomib-dexamethasone (DaraVd) in multiple myeloma patients refractory to lenalidomideI Rizzello, I Sacchetti, S Barbato, et al.
Cancer Medicine|November 26, 2024
Clinical Presentation and Long-Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective StudyK Mancuso, R Mina, S Rocchi, et al.
Leukemia|October 23, 2015
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active diseaseE Zamagni, C Nanni, F Gay, et al.
Pageof 2